Harvard Bioscience, Inc. (HBIO): Price and Financial Metrics
Harvard Bioscience, Inc. (HBIO)
Today's Latest Price: $2.85 USD
Updated Jun 5 4:00pm
Add HBIO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
HBIO Stock Summary
- With a year-over-year growth in debt of -12.48%, Harvard Bioscience Inc's debt growth rate surpasses just 18.47% of about US stocks.
- Over the past twelve months, HBIO has reported earnings growth of -403.17%, putting it ahead of only 4.24% of US stocks in our set.
- The volatility of Harvard Bioscience Inc's share price is greater than that of merely 19.22% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to HBIO, based on their financial statements, market capitalization, and price volatility, are BDC, CAMP, VAPO, STIM, and LNDC.
- Visit HBIO's SEC page to see the company's official filings. To visit the company's web site, go to www.harvardbioscience.com.
HBIO Stock Price Chart More Charts
HBIO Price/Volume Stats
| Current price | $2.85 | 52-week high | $3.50 |
| Prev. close | $2.76 | 52-week low | $1.39 |
| Day low | $2.79 | Volume | 132,190 |
| Day high | $2.85 | Avg. volume | 164,594 |
| 50-day MA | $2.57 | Dividend yield | N/A |
| 200-day MA | $2.76 | Market Cap | 109.38M |
Harvard Bioscience, Inc. (HBIO) Company Bio
Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science research. The company was founded in 1901 and is based in Holliston, Massachusetts.
HBIO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $2.85 | $1.79 | -35% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Harvard Bioscience Inc. To summarize, we found that Harvard Bioscience Inc ranked in the 38th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 34.5%. The most interesting components of our discounted cash flow analysis for Harvard Bioscience Inc ended up being:
- The stock's equity weight, or the proportion of capital from equity relative to debt, is 64. Its equity weight surpasses that of just 17.02% of free cash flow generating stocks in the Healthcare sector.
- Harvard Bioscience Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.54. This coverage rate is greater than that of merely 19.05% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -36% |
| 1% | -35% |
| 2% | -35% |
| 3% | -34% |
| 4% | -34% |
| 5% | -33% |
BDX, SGRY, TARO, USPH, and ITGR can be thought of as valuation peers to HBIO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...